Irina Antonijevic, a director at Biohaven Ltd (BHVN, Financial), has sold 11,000 shares of the company on December 29, 2023, according to a recent SEC Filing. Biohaven Ltd is a clinical-stage biopharmaceutical company engaged in the identification and development of clinical candidates in diseases with significant unmet need. The company's portfolio includes multiple late-stage drug candidates targeting neurological diseases, including rare disorders.
The insider's transaction history over the past year shows that Irina Antonijevic has sold a total of 11,000 shares and has not made any purchases of the company's stock.
The insider transaction history for Biohaven Ltd indicates a trend of more insider buying than selling over the past year. There have been 6 insider buys and only 1 insider sell during this period.
On the date of the insider's most recent transaction, shares of Biohaven Ltd were trading at $41.79 each, giving the company a market capitalization of $3.434 billion.
Investors often monitor insider buying and selling as it can provide insights into a company's internal conditions and the confidence level of its executives and directors. The data provided here reflects the transactions as filed and does not include any analysis of the potential reasons or implications of these trades.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
